NASDAQ$VIR
Vir Biotechnology Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Vir Biotechnology reported Q1 2025, revenue of $3M, a net loss of $68.4M, diluted EPS of ($0.49).
For Q1 2025, Vir Biotechnology reported revenue of $3M, a net loss of $68.4M, diluted EPS was ($0.49). The filing highlights segment performance, liquidity, and management commentary on the period.
- Revenue $3M.
- Net loss $68.4M.
- Diluted EPS ($0.49).
Headline financials
Revenue & EPS history
Vir · Revenue · Quarterly
$3.03M
Revenue by segment
Vir · $2.35M total across 2 segments · Q3 2023
- Grant revenue$6.74M+117.3%286.7%
- License & collaboration revenue-$4.39M-101.4%-186.7%
Forward guidance
Life-sciences filers emphasize pipeline milestones, regulatory paths, and cash runway; product revenue may be limited or emerging.
Tailwinds
- Pipeline progress and partnership optionality.
- Cash balances funding operations into catalysts.
- Commercial launches where approved.
Headwinds
- Trial failure or regulatory delay risk.
- Reimbursement and competitive pressure.
- Dilution from equity raises.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+2.0%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
43%
12 / 28 earnings
Positive
+27.7%
Q4 2025
Best reaction
-15.1%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -7.2% | -13.7% | |
| Q4 2025 | +27.7% | +22.3% | +20.6% | |
| Q3 2025 | -5.6% | -8.9% | +8.3% | |
| Q1 2025 | -3.4% | -16.2% | -2.9% | |
| Q4 2024 | -11.8% | -10.9% | -27.2% | |
| Q3 2024 | +21.8% | +26.8% | +4.7% | |
| Q2 2024 | -9.4% | -15.4% | -18.7% | |
| Q1 2024 | +18.9% | +13.6% | +17.5% | |
| Q4 2023 | +14.0% | +13.1% | -0.6% | |
| Q3 2023 | +12.5% | +8.3% | +24.4% | |
| Q2 2023 | -3.0% | -4.8% | -10.9% | |
| Q1 2023 | -3.5% | -4.5% | +7.5% | |
| Q4 2022 | -14.8% | -15.6% | -16.7% | |
| Q3 2022 | +15.0% | +20.3% | +23.7% | |
| Q2 2022 | +2.0% | -4.9% | -25.9% | |
| Q1 2022 | -3.1% | -1.4% | +12.5% | |
| Q4 2021 | +0.1% | -13.7% | -21.5% | |
| Q3 2021 | -15.1% | -11.7% | +20.4% | |
| Q2 2021 | +3.3% | +10.5% | +32.0% | |
| Q1 2021 | -1.0% | -8.5% | +3.5% | |
| Q4 2020 | -4.2% | -11.7% | -21.2% | |
| Q3 2020 | +8.2% | +5.8% | +26.0% | |
| Q2 2020 | -0.6% | -0.9% | -46.8% | |
| Q2 2019 | -0.6% | -0.9% | -46.8% | |
| Q1 2020 | -1.9% | -3.1% | +7.2% | |
| Q1 2019 | -1.9% | -3.1% | +7.2% | |
| Q4 2019 | +11.5% | +11.4% | +6.0% | |
| Q3 2019 | -3.0% | -0.5% | -3.7% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro